InflaRx NV Dossier
Qualitative Analysis
Business overview
InflaRx N.V. is a clinical-stage biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system. The company applies its proprietary anti-C5a and anti-C5aR technologies to discover, develop, and commercialize highly potent and specific inhibitors of the complement activation factor C5a and its receptor, C5aR. Its lead pipeline asset is izicopan (INF904), an orally administered small molecule inhibitor of C5aR developed for hidradenitis suppurativa (HS) and other inflammation and immunology (I&I) indications. The company also developed Gohibic (vilobelimab), an intravenously delivered first-in-class anti-C5a monoclonal antibody available in the US under an Emergency Use Authorization (EUA) for COVID-19-induced ARDS.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
In January 2026, InflaRx announced a major strategic realignment to focus its resources on its oral C5a receptor inhibitor, izicopan, as its primary pipeline asset. The company is prioritizing izicopan's development in ANCA-associated vasculitis (AAV) and other complement-mediated renal diseases, while scaling back commercial spending on Gohibic (vilobelimab).
Expected impact: Significantly improves capital efficiency, extends the cash runway through 2029, and concentrates resources on the highest-value asset with potential best-in-class properties.
To support its capital-efficient execution strategy, InflaRx implemented a workforce reduction of approximately 30% and executed substantial spending cuts. This included streamlining the organizational structure, modifying or terminating certain third-party contracts, and writing down vilobelimab inventory.
Expected impact: Creates a significantly leaner cost structure, leading to sustained reductions in operating expenses and extending the operational runway.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Staidson is developing BDB-001, an anti-C5a antibody originating from the same cell line as vilobelimab, in China. In July 2025, Staidson reported positive Phase 1/2 data for BDB-001 in AAV and plans to advance it into Phase 3 trials.
Terms: InflaRx is entitled to receive mid-single-digit percentage royalties on future net sales of Staidson's BDB-001 in AAV in China, as well as 10% royalties on net sales for COVID-19 treatment.
InflaRx maintains operational capability and collaboration to support the ongoing BARDA-funded 'JUST BREATHE' Phase 2 platform clinical trial evaluating host-directed therapeutics, including vilobelimab, in hospitalized patients with acute respiratory distress syndrome (ARDS).
Terms: Supported by federal funding grants under the BARDA clinical platform program.